Kansas City, Missouri 64128

  • EMR Ulcer


Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for early adenocarcinoma of the esophagus.


Inclusion Criteria: - Category 4-high-grade intraepithelial neoplasia - Ages 18 or older - signed Informed Consent Form - signed Health Insurance Portability and Accountability Act (HIPAA) Authorization Form Exclusion Criteria: - Clinically relevant data suggesting an unknown disease and requiring further evaluation by the Primary Investigator. - Patients with renal failure or organ transplants. - Patients who have known allergic reactions to Proton Pump Inhibitors (PPI). - Participation in another study that would interfere with study endpoints within 30 days prior to screening. - Previous enrollment into the current study. - Patient is the Investigator, his family member or employee at the investigational site. - Patient known or suspected to be involved in alcohol or drug abuse. - Known or suspected history of non-compliance with medications. - Inability to follow the procedures of the study (e.g., due to language problems, psychological disorders) - Patients receiving prohibited concomitant medications including PPIs, H2-blockers, sucralfate, misoprostol. - Patients receiving prohibited concomitant medications including clopidogrel, ketoconazole, digoxin, diazepam, warfarin, phenytoin, emtricitabine/nelfinavir/tenofovir, atazanavir, citalopram, emtricitabine/rilpivirine/tenofovir, rilpivirine, nelfinavir, tricyclic antidepressants, baclofen, tacrolimus, cyclosporine, cilostazol, disulfiram, methotrexate, voriconazole. - Pregnancy or intention to become pregnant during the course of study, breast feeding, or unwillingness to use a highly effective means of contraception (oral contraception or intrauterine device). - Prescription Non-steroidal anti-inflammatory Drug (NSAID) or aspirin use: The patient must be able to stop these meds 1 week prior to screening and during treatment. - History of upper gastrointestinal surgery, Zollinger-Ellison syndrome, esophageal stricture, peptic stricture, duodenal and ⁄ or gastric ulcer, esophageal motility disorders, Inflammatory Bowel Disease (IBD), AIDS, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease, liver disease, active malignant disease, Scleroderma, diabetes mellitus, autonomic or peripheral neuropathy, myopathy, functional bowel disorder or any underlying disease or medication that might affect the lower esophageal sphincter pressure or increase the acid clearance time. - Subject unable or unwilling to fully complete all stages of the study. - Unable to sign informed consent or inability to give fully informed consent due to language problems, psychological disorder or mental deficiency.



Primary Contact:

April Higbee, BSN
Phone: 816 861-4700 ext. 57456
Email: April.Higbee@va.gov

Backup Contact:


Location Contact:

Kansas City, Missouri 64128
United States

Higbee, BSN
Phone: 816-861-4700

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: July 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.